Serum high mobility group box protein 1 as a clinical marker for ovarian cancer

Neoplasma

Volumn 61, Issue 5, 2014, Pages 579-584

  Li, Y ^a   Tian, J ^a   Fu, X ^a   Chen, Y ^a   Zhang, W ^a   Yao, H ^a   Hao, Q ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

High mobility group box chromosomal protein 1; Ovarian cancer; Prognosis

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CALIBRATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MIDDLE AGED; OVARY CANCER; AGED; BLOOD; OVARY TUMOR; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; FEMALE; HMGB1 PROTEIN; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84907288194     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_070     Document Type: Article

References (33)

1. Bast RJ, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9: 415–28. http://dx.doi.org/10.1038/nrc2644
2. Yotov WV, St-Arnaud R. Nucleotide sequence of a mouse cDNA encoding the nonhistone chromosomal high mobility group protein-1 (HMG1). Nucleic Acids Res 1992; 20: 3516. http://dx.doi.org/10.1093/nar/20.13.3516
3. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331–42. http://dx.doi.org/10.1038/nri1594
4. Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, et al. New EMBO members‘ review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. Embo J 2001; 20: 4337–40. http://dx.doi.org/10.1093/emboj/20.16.4337
5. Thanos D, Maniatis T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 1992; 71: 777–89. http://dx.doi.org/10.1016/0092-8674(92)90554-P
6. Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, et al. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol 2003; 23: 2225–38. http://dx.doi.org/10.1128/MCB.23.7.2225-2238.2003
7. Fashena SJ, Reeves R, Ruddle NH. A poly(dA-dT) upstream activating sequence binds high-mobility group I protein and contributes to lymphotoxin (tumor necrosis factor-beta) gene regulation. Mol Cell Biol 1992; 12: 894–903.
8. Yao X, Zhao G, Yang H, Hong X, Bie L, et al. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010; 136: 677–84. http://dx.doi.org/10.1007/s00432-009-0706-1
9. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008; 216: 167–75. http://dx.doi.org/10.1002/path.2391
10. Liu PL, Tsai JR, Hwang JJ, Chou SH, Cheng YJ, et al. High-mobility group box 1-mediated matrix metalloproteinase- 9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol 2010; 43: 530–38. http://dx.doi.org/10.1165/rcmb.2009-0269OC
11. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009; 7: 38. http://dx.doi.org/10.1186/1479-5876-7-38
12. Chen J, Liu X, Zhang J, Zhao Y. Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirusmediated RNA interference. J Cell Physiol 2012; 227: 3629–38. http://dx.doi.org/10.1002/jcp.24069
13. Chen J, Xi B, Zhao Y, Yu Y, Zhang J, et al. High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer. Gynecol Oncol 2012; 126: 109–17. http://dx.doi.org/10.1016/j.ygyno.2012.03.051
14. Lee H, Song M, Shin N, Shin CH, Min BS, et al. Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One 2012; 7: e34318. http://dx.doi.org/10.1371/journal.pone.0034318
15. Sheng X, Du X, Zhang X, Li D, LU C, et al. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat Med J 2009; 50: 455–64. http://dx.doi.org/10.3325/cmj.2009.50.455
16. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932–36. http://dx.doi.org/10.1038/nature04478
17. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. Embo Rep 2004; 5: 825–30. http://dx.doi.org/10.1038/sj.embor.7400205
18. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191–95. http://dx.doi.org/10.1038/nature00858
19. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008; 40: 446–52. http://dx.doi.org/10.1016/j.dld.2007.11.024
20. Poser I, Golob M, Buettner R, Bosserhoff AK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003; 23: 2991–98. http://dx.doi.org/10.1128/MCB.23.8.2991-2998.2003
21. Bassi R, Giussani P, Anelli V, Colleoni T, Pedrazzi M, et al. HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J Neurooncol 2008; 87: 23–33. http://dx.doi.org/10.1007/s11060-007-9488-y
22. Kawahara N, Tanaka T, Yokomizo A, Nanri H, Ono M, et al. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 1996; 56: 5330–33.
23. Volp K, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006; 55: 234–42. http://dx.doi.org/10.1136/gut.2004.062729
24. Ito N, Demarco RA, Mailliard RB, Han J, Rabinowich H, et al. Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 2007; 81: 75–83. http://dx.doi.org/10.1189/jlb.0306169
25. Ugrinova I, Pashev IG, Pasheva EA. Nucleosome binding properties and Co-remodeling activities of native and in vivo acetylated HMGB-1 and HMGB-2 proteins. Biochemistry-Us 2009; 48: 6502–07. http://dx.doi.org/10.1021/bi9004304
26. Pasheva E, Sarov M, Bidjekov K, Ugrinova I, Sarg B, et al. In vitro acetylation of HMGB-1 and -2 proteins by CBP: the role of the acidic tail. Biochemistry-Us 2004; 43: 2935–40. http://dx.doi.org/10.1021/bi035615y
27. Evankovich J, Cho SW, Zhang R, Cardinal J, Dhupar R, et al. High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem 2010; 285: 39888–97. http://dx.doi.org/10.1074/jbc.M110.128348
28. Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 2013; 93: 865–73. http://dx.doi.org/10.1189/jlb.1212662
29. Taguchi A, Blood DC, Del TG, Canet A, Lee DC, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354–60. http://dx.doi.org/10.1038/35012626
30. Lotze MT, Demarco RA. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs 2003; 4: 1405–09.
31. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol 2005; 26: 381–87. http://dx.doi.org/10.1016/j.it.2005.04.009
32. Tafani M, Schito L, Pellegrini L, Villanova L, Marfe G, et al. Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis 2011; 32: 1167–75. http://dx.doi.org/10.1093/carcin/bgr101
33. Mignogna MD, Fedele S, Lo RL, Lo ML, Bucci E. Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol 2004; 40: 120–30. http://dx.doi.org/10.1016/j.oraloncology.2003.08.001